International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia
References
- Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nature Reviews Disease Primers. 2017; 3: 17093. DOI: 10.1038/nrdp.2017.93
- Centers for Disease Control and Prevention. Tier 1 Genomic Applications Toolkit for Public Health Departments. 2014.
https://www.cdc.gov/genomics/implementation/toolkit/index.htm . - Representatives of the Global Familial Hypercholesterolemia C, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA cardiology. 2020; 5(2): 217–29. DOI: 10.1001/jamacardio.2019.5173
- Watts GF, Gidding SS, Mata P, Pang J, Sullivan DR, Yamashita S, et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nature Reviews Cardiology. 2020; 17: 360–77. DOI: 10.1038/s41569-019-0325-8
- Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology. 2023; 20: 845–69. DOI: 10.1038/s41569-023-00892-0
- Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015; 10(1): 21. DOI: 10.1186/s13012-015-0209-1
- Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015; 36(36): 2425–37. DOI: 10.1093/eurheartj/ehv157
- Gidding SS, Wiegman A, Groselj U, Freiberger T, Peretti N, Dharmayat KI, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. European Journal of Preventive Cardiology. 2022; 29(18): 2301–11. DOI: 10.1093/eurjpc/zwac200
- Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. The lancet Diabetes & endocrinology. 2016; 4(10): 850–61. DOI: 10.1016/s2213-8587(16)30041-9
- Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023; 44(25): 2277–91. DOI: 10.1093/eurheartj/ehad197
- Thompson GR. Use of apheresis in the age of new therapies for familial hypercholesterolaemia. Curr Opin Lipidol. 2021; 32(6): 363–9. DOI: 10.1097/mol.0000000000000784
- Ray K, Ference B, Séverin T, Blom D, Nicholl SS, Harada-Shiba M, et al. World Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022; 17(1): 75. DOI: 10.5334/gh.1154
- Watts GF, Pang J. The evolving model of care for familial hypercholesterolaemia. European Journal of Preventive Cardiology. 2017; 24(16): 1729–32. DOI: 10.1177/2047487317721656
DOI: https://doi.org/10.5334/gh.1291 | Journal eISSN: 2211-8179
Language: English
Submitted on: Nov 16, 2023
Accepted on: Dec 28, 2023
Published on: Jan 25, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2024 Gerald F. Watts, Laney K. Jones, Mitchell N. Sarkies, Jing Pang, Samuel S. Gidding, Peter Libby, Raul D. Santos, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.